欧洲皮肤病与性病学会(EADV)发起的大疱性类天疱疮管理S2 K指南更新
大疱性类天疱疮(BP)是最常见的自身免疫性表皮下大疱病,多见于老年人,与神经系统疾病显著相关。EADV自身免疫性大疱病工作组基于新临床信息和证据更新管理指南,推荐高强效外用糖皮质激素作为主要治疗,口服泼尼松0.5 mg/kg/天为替代方案,并汇总了免疫抑制剂、多西环素、氨苯砜、B细胞清除治疗、静脉免疫球蛋白、奥马珠单抗和度普利尤单抗的使用建议。
要点
- 高强效外用糖皮质激素推荐作为BP的主要治疗(尽可能使用)。
- 口服泼尼松0.5 mg/kg/天是推荐的替代方案。
- 存在禁忌或抵抗时,可推荐甲氨蝶呤、硫唑嘌呤、吗替麦考酚酯或霉酚酸等免疫抑制治疗。
核心结论
- BP管理指南已更新,汇总了基于证据和专家意见的建议,有助于临床实践。
研究设计与样本
- 欧洲皮肤病与性病学会(EADV)自身免疫性大疱病工作组基于新临床信息、诊断工具和干预措施的新证据更新指南,建议基于证据或专家意见,并纳入全体工作组成员的同意程度。
主要发现
- 治疗取决于BP严重程度和患者合并症。
- 高强效外用糖皮质激素推荐作为主要治疗(尽可能使用);口服泼尼松0.5 mg/kg/天是推荐的替代方案。
- 存在禁忌或抵抗时,可推荐甲氨蝶呤、硫唑嘌呤、吗替麦考酚酯或霉酚酸等免疫抑制治疗。
- 多西环素和氨苯砜的使用存在争议,尤其可推荐用于有口服糖皮质激素禁忌的患者。
- 难治性病例可考虑B细胞清除治疗和静脉免疫球蛋白;奥马珠单抗和度普利尤单抗近期显示有希望的结果。
关键数值与推荐
- 高强效外用糖皮质激素推荐作为主要治疗(尽可能使用)。
- 口服泼尼松0.5 mg/kg/天是推荐的替代方案。
- 存在禁忌或抵抗时,可推荐甲氨蝶呤、硫唑嘌呤、吗替麦考酚酯或霉酚酸等免疫抑制治疗。
- 多西环素和氨苯砜的使用存在争议,尤其可推荐用于有口服糖皮质激素禁忌的患者。
- 难治性病例可考虑B细胞清除治疗和静脉免疫球蛋白;奥马珠单抗和度普利尤单抗近期显示有希望的结果。
临床怎么用
- 治疗应根据BP严重程度和患者合并症选择。
- 尽可能使用高强效外用糖皮质激素作为主要治疗。
- 口服泼尼松0.5 mg/kg/天可作为替代方案。
- 存在禁忌或抵抗时,可推荐甲氨蝶呤、硫唑嘌呤、吗替麦考酚酯或霉酚酸等免疫抑制治疗。
- 多西环素和氨苯砜尤其可推荐用于有口服糖皮质激素禁忌的患者;难治性病例可考虑B细胞清除治疗和静脉免疫球蛋白。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. OBJECTIVES AND METHODOLOGY: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. RESULTS: Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. CONCLUSIONS: The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
引用
- Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022. PMID: 35766904. doi:10.1111/jdv.18220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。